Document is current

Article History

Received: 28 April 2024

Accepted: 18 November 2024

First Online: 18 December 2024

Competing interests

: E.B.: grants from Gilead to institution; personal fees from Eli Lilly; C.B.: fees or honoraria from Novartis, Roche and Eli Lilly; A.F.: advisory boards: Roche, Novartis, Eli Lilly, Pfizer, MSD, Pierre Fabre, Eisai, Gilead, Seagen, AstraZeneca, Exact Sciences; consulting fees: Dompé Farmaceutici S.p.A.; F.M.: consulting fees: Roche, Novartis, AstraZeneca, Daiichy Sankyo, SeaGen, MSD, Eli Lilly, Pfizer, and Pierre Fabre; travel grants: Roche and AstraZeneca; from May 15th, 2023, F.M. is Roche employee (all the disclosed activities are outside the submitted work); M.D.L.: speaker’s honoraria, consulting honoraria, and advisory board honoraria: Novartis, Eli Lilly, Pfizer, Roche, Sophos, Genetic, Menarini, Daiichi-Sankyo, Seagen, Pierre Fabre, GSK and Takeda; G.A.: research and medical writing: AstraZeneca; advisory boards, travel grants, activities as a speaker, consultancy: AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Gilead, Exact Science, Novartis, Roche, Seagen, Viatris; L.D.M.: institutional grants: Eli Lilly, Novartis, Roche, Daiichi Sankyo, Seagen, Astra Zeneca, Gilead, Pierre Fabre; consulting fees: Eli Lilly, Gilead, Daiichi Sankyo; payment or honoraria for lectures, presentations, speakers bureaus: Roche, Novartis, Pfizer, Eli Lilly, AstraZeneca, MSD, Seagen, Gilead, Pierre Fabre, Eisai, Exact Sciences, Ipsen, GSK, Agendia, Menarini Stemline; support for attending meetings and/or travel: Roche, Pfizer, Eisai, Daiichi Sankyo, AstraZeneca, Gilead; Participation on a Data Safety Monitoring Board or Advisory Board: Novartis, Roche, Eli Lilly, Pfizer, Daiichi Sakyo, Exact Sciences, Gilead, Pierre Fabre, Eisai, AstraZeneca, Agendia, GSK, Seagen, Olema, MSD, Menarini Stemline; L.G.: consulting or advisory role: AstraZeneca, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Incyte, Novartis, Pfizer, Merck Sharp & Dohme, Menarini Stemline, Abbvie; research funding: Menarini Silicon Biosystems Patents, Royalties; travel expenses: Menarini Stemline; F.P.: honoraria for advisory boards, activities as a speaker, travel grants, research grants from Amgen, AstraZeneca, Daiichi Sankyo, Celgene, Eisai, Eli Lilly, Exact Sciences, Gilead, Ipsen, Menarini, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Seagen, Takeda, Viatris; research funding from AstraZeneca, Eisai, Roche, outside the submitted work. The remaining authors have no conflict to disclose.